Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

oncolytic adenovirus ICOVIR5-infected allogeneic mesenchymal stem cells

A preparation of bone marrow-derived allogeneic mesenchymal stem cells (MSCs) infected with the oncolytic, replication-competent adenovirus ICOVIR5, with potential antineoplastic activity. Upon infusion of the oncolytic adenovirus ICOVIR5-infected allogeneic MSCs, these cells target the adenovirus to tumors. The oncolytic virus then selectively transfects and replicates in the tumor cells causing a direct cytotoxic effect and lysis of the tumor cells. In addition, the viral infection and the subsequent release of tumor-associated antigens (TAAs) upon lysis may stimulate an immune response against the tumor cells. This may lead to an inhibition of cancer cell proliferation. ICOVIR-5, a virus derived from wild-type human adenovirus serotype 5 (Had5), has been modified to selectively replicate in tumor cells that have a deregulated retinoblastoma/E2F pathway.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:oncolytic adenovirus ICOVIR5-infected allogeneic MSCs
Foreign brand name:AloCelyvir
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search